[The use of Lamiktal in treating epilepsy in children and adolescents].
Antiepileptic effects of lamiktal (lamotrigine) produced in Great Britain (Wellcome) was tried in 7 children aged 3-14 and 3 adults aged 18-30. Of them 6 patients and 4 patients suffered from temporal polymorphic fits and general paroxysms, respectively. Upon 3-month follow-up it was found that the fits discontinued in 4 patients, frequency of the paroxysms reduced or they became abortive in 6 cases. EEG changes were insignificant. No side effects occurred. Lamiktal is recommended in polymorphic seizures in children and adults, in failure of other anticonvulsants in patients frequently affected with epileptic paroxysms.
Solovykh
N N
NN
Korotkov
A G
AG
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004569:Electroencephalography / Q000187:drug effects; D004832:Epilepsy, Absence / Q000188:drug therapy*; D004829:Epilepsy, Generalized / Q000188:drug therapy*; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D012074:Remission Induction; D014227:Triazines / Q000627:therapeutic use*
D000927:Anticonvulsants; D014227:Triazines; D000077213:Lamotrigine
Primenenie lamiktala v lechenii épilepsii u deteĭ i podrostkov.